Evidence map›Paper›PMID 42733862›Full record

ArticleMaterials today. Bio2026

Biohybrid nanovesicle-mediated targeted delivery of HSP90 inhibitor for enhanced sorafenib therapy of hepatocellular carcinoma after radiofrequency ablation.

Angfeng Jiang, Xianfei Zhou, Jinchao Zhao, Shaoming Zou, Junkang Ding, Junyi Zhang, Lei Lei, Qiao Jin, Zhe Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Angfeng JiangDepartment of General Surgery, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine , International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Xianfei ZhouDepartment of General Surgery, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine , International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Jinchao ZhaoDepartment of General Surgery, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine , International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Shaoming ZouDepartment of General Surgery, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine , International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Junkang DingDepartment of General Surgery, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine , International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Junyi ZhangDepartment of General Surgery, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine , International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Lei LeiDepartment of General Surgery, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine , International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Qiao JinMOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, China.
Zhe TangDepartment of General Surgery, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine , International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) presents significant therapeutic challenges due to enhanced liver cancer stem cell (LCSC) stemness and sorafenib resistance after radiofrequency ablation (RFA). To address these limitations, biohybrid nanovesicles (hNVs) are prepared by fusing milk-derived exosomes with sorafenib-resistant LM3 cell membranes as nanovectors for targeted delivery of the HSP90 inhibitor alvespimycin (17-DMAG). The hNVs exhibit enhanced tumor-homing capability through homologous targeting, achieving 3.2-fold higher tumor accumulation compared to unmodified exosomes. RFA of HCC significantly upregulates the expression of HSP90, leading to enhanced LCSC stemness and sorafenib resistance. In vitro and in vivo studies demonstrate that 17-DMAG loaded hNVs (17-DMAG@hNVs) effectively suppress LCSC stemness by downregulating HSP90 and its downstream signal pathways (TGF-β/Smad3 and JAK/STAT3), thereby restoring sorafenib sensitivity. Therefore, 17-DMAG@hNVs remarkably enhance the therapeutic efficacy of sorafenib after RFA of HCC. The reversal of LCSC stemness by inhibiting HSP90 expression using 17-DMAG@hNVs provides a promising approach to overcome sorafenib resistance for enhanced therapy of HCC after RFA.

Indexed as

Drug resistanceHepatocellular carcinomaNanovesicleRadiofrequency ablationSorafenib

Identifiers

PMID42733862
PMCPMC13571697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.